OpRegen is a Cell Therapy owned by F. Hoffmann-La Roche, and is involved in 2 clinical trials, of which 1 was completed, and 1 is planned.
OpRegen replaces the layer of damaged RPE cells that support and nourish the retina. RPE cells derived from human embryonic stem cells restore the subretinal anatomy and re-establishes the critical interaction between the RPE and the photoreceptors, which is fundamental to the eye sight.
The revenue for OpRegen is expected to reach a total of $184m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the OpRegen NPV Report.
OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.
Lineage Cell Therapeutics Overview
Lineage Cell Therapeutics (Lineage) formerly known as BioTime, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. The company lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration, Opc1 in acute spinal cord injury, and Vac2 for non-small cell lung cancer. The company has subsidiaries in Israel, Singapore, and the US. Lineage is headquartered in Carlsbad, California, the US.
The company reported revenues of (US Dollars) US$4.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.8 million in FY2020. The operating loss of the company was US$48.7 million in FY2021, compared to an operating loss of US$26.5 million in FY2020. The net loss of the company was US$43 million in FY2021, compared to a net loss of US$20.7 million in FY2020. The company reported revenues of US$3 million for the third quarter ended September 2022, a decrease of 34.2% over the previous quarter.
Quick View – OpRegen
|Highest Development Stage|